OMER

Omeros Corporation

$14.30

chg

-0.08 (-0.56%)

quotes and stock data may be delayed 15 minutes

52 wk low

9.25

52 wk hi

23.85

Cash

$100.5M

Burn Rate (Qtr)

$35.1M

Mkt Cap

$891.3m

Avg Volume

387,160

*cash/burn updated:

Q1'21

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information.

No drug found

We have found any drug for this company yet

Drug | Disease (links)

Stage (next event)

Catalyst Date

Loading Catalysts...

search in progress

Pipeline powered by

OMER

BPIQ_Logo_RGB-01.jpg

Company Profile

Omeros is a Seattle-based biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.

Recent Posts

See what the community is saying - click to see full post.

EHA2021 Investor Hub

OMER - Omeros Submits its Biologics License Application to U.S. FDA for Narsoplimab in HSCT-TMA

OMER - Omeros Corporation Reports Third Quarter 2020 Financial Results